MyriaMed

MyriaMed is a biotechnology company based in Göttingen, Germany, specializing in the development of advanced human heart muscle models for drug discovery and safety pharmacology. Utilizing induced pluripotent stem cell (iPSC) technology, the company produces engineered heart tissue (EHT) that mimics human cardiac physiology more accurately than traditional animal models. Their proprietary MyriaMesh and MyriaScreen platforms enable high-throughput screening of drug candidates for cardiotoxicity and efficacy in treating cardiovascular diseases. Beyond screening services, MyriaMed is actively involved in research for regenerative medicine applications, aiming to develop cell-based therapies for heart repair. The company serves pharmaceutical and biotech partners by providing predictive human-relevant data early in the drug development process. This approach helps to reduce the reliance on animal testing while improving the success rate of clinical trials.